...
search icon
repl-img

Replimune Group Inc, Common Stock

REPL

NSQ

$13.71

-$0.27

(-1.93%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.07B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
627.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.19
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.92 L
$17 H
$13.71

About Replimune Group Inc, Common Stock

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameREPLSectorS&P500
1-Week Return0.15%-0.46%0.38%
1-Month Return8.64%5.69%1.64%
3-Month Return14.06%0.07%5.64%
6-Month Return41.05%0.03%16.44%
1-Year Return94.47%3.12%22.25%
3-Year Return-24.88%10.61%34.76%
5-Year Return-18.34%46.81%85.78%
10-Year Return-9.56%109.43%194.65%

Financials

Mar '20Mar '21Mar '22Mar '23Mar '245YR TREND
Total Revenue-----[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Cost of Revenue1.81M4.14M4.58M2.45M2.65M[{"date":"2020-03-31","value":39.5,"profit":true},{"date":"2021-03-31","value":90.47,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":53.49,"profit":true},{"date":"2024-03-31","value":58.03,"profit":true}]
Gross Profit(1.81M)(4.14M)(4.58M)(2.45M)(2.65M)[{"date":"2020-03-31","value":-180700000,"profit":false},{"date":"2021-03-31","value":-413900000,"profit":false},{"date":"2022-03-31","value":-457500000,"profit":false},{"date":"2023-03-31","value":-244700000,"profit":false},{"date":"2024-03-31","value":-265500000,"profit":false}]
Gross Margin-----[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Operating Expenses53.11M77.15M115.14M174.17M234.77M[{"date":"2020-03-31","value":22.62,"profit":true},{"date":"2021-03-31","value":32.86,"profit":true},{"date":"2022-03-31","value":49.04,"profit":true},{"date":"2023-03-31","value":74.18,"profit":true},{"date":"2024-03-31","value":100,"profit":true}]
Operating Income(56.20M)(79.95M)(118.31M)(177.08M)(234.77M)[{"date":"2020-03-31","value":-5619800000,"profit":false},{"date":"2021-03-31","value":-7995500000,"profit":false},{"date":"2022-03-31","value":-11831400000,"profit":false},{"date":"2023-03-31","value":-17708000000,"profit":false},{"date":"2024-03-31","value":-23477300000,"profit":false}]
Total Non-Operating Income/Expense489.00K(3.98M)(1.95M)(1.08M)12.73M[{"date":"2020-03-31","value":3.84,"profit":true},{"date":"2021-03-31","value":-31.23,"profit":false},{"date":"2022-03-31","value":-15.28,"profit":false},{"date":"2023-03-31","value":-8.45,"profit":false},{"date":"2024-03-31","value":100,"profit":true}]
Pre-Tax Income(52.63M)(80.87M)(118.04M)(174.00M)(215.39M)[{"date":"2020-03-31","value":-5262500000,"profit":false},{"date":"2021-03-31","value":-8087000000,"profit":false},{"date":"2022-03-31","value":-11803600000,"profit":false},{"date":"2023-03-31","value":-17399600000,"profit":false},{"date":"2024-03-31","value":-21538600000,"profit":false}]
Income Taxes1.90M2.40M1.16M288.00K408.00K[{"date":"2020-03-31","value":79.46,"profit":true},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":48.6,"profit":true},{"date":"2023-03-31","value":12.03,"profit":true},{"date":"2024-03-31","value":17.04,"profit":true}]
Income After Taxes(54.53M)(83.27M)(119.20M)(174.28M)(215.79M)[{"date":"2020-03-31","value":-5452800000,"profit":false},{"date":"2021-03-31","value":-8326500000,"profit":false},{"date":"2022-03-31","value":-11920000000,"profit":false},{"date":"2023-03-31","value":-17428400000,"profit":false},{"date":"2024-03-31","value":-21579400000,"profit":false}]
Income From Continuous Operations(52.63M)(80.87M)(118.04M)(174.28M)(215.79M)[{"date":"2020-03-31","value":-5262500000,"profit":false},{"date":"2021-03-31","value":-8087000000,"profit":false},{"date":"2022-03-31","value":-11803600000,"profit":false},{"date":"2023-03-31","value":-17428400000,"profit":false},{"date":"2024-03-31","value":-21579400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}]
Net Income(52.63M)(80.87M)(118.04M)(174.28M)(215.79M)[{"date":"2020-03-31","value":-5262500000,"profit":false},{"date":"2021-03-31","value":-8087000000,"profit":false},{"date":"2022-03-31","value":-11803600000,"profit":false},{"date":"2023-03-31","value":-17428400000,"profit":false},{"date":"2024-03-31","value":-21579400000,"profit":false}]
EPS (Diluted)(1.52)(1.73)(2.26)(3.00)(3.24)[{"date":"2020-03-31","value":-152,"profit":false},{"date":"2021-03-31","value":-173,"profit":false},{"date":"2022-03-31","value":-226,"profit":false},{"date":"2023-03-31","value":-300,"profit":false},{"date":"2024-03-31","value":-324,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

REPL
Cash Ratio 9.87
Current Ratio 10.11

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

REPL
ROA (LTM) -27.07%
ROE (LTM) -50.32%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

REPL
Debt Ratio Lower is generally better. Negative is bad. 0.23
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.77

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

REPL
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.75
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Replimune Group Inc share price today?

Replimune Group Inc (REPL) share price today is $13.71

Can Indians buy Replimune Group Inc shares?

Yes, Indians can buy shares of Replimune Group Inc (REPL) on Vested. To buy Replimune Group Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in REPL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Replimune Group Inc be purchased?

Yes, you can purchase fractional shares of Replimune Group Inc (REPL) via the Vested app. You can start investing in Replimune Group Inc (REPL) with a minimum investment of $1.

How to invest in Replimune Group Inc shares from India?

You can invest in shares of Replimune Group Inc (REPL) via Vested in three simple steps:

  • Click on Sign Up or Invest in REPL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Replimune Group Inc shares
What is Replimune Group Inc 52-week high and low stock price?

The 52-week high price of Replimune Group Inc (REPL) is $17. The 52-week low price of Replimune Group Inc (REPL) is $4.92.

What is Replimune Group Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Replimune Group Inc (REPL) is 2.75

What is the Market Cap of Replimune Group Inc?

The market capitalization of Replimune Group Inc (REPL) is $1.07B

What is Replimune Group Inc’s stock symbol?

The stock symbol (or ticker) of Replimune Group Inc is REPL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top